Recall(New to the series?)
Single GLP-1 agonists hit one receptor: GLP-1R. That drives insulin secretion, glucagon suppression, gastric slowing, and appetite reduction through the brain. For the full receptor breakdown, see The Receptor Game.
Single GLP-1 receptor agonists are where the class started. Before dual agonists, before oral non-peptides, before triple agonism — these drugs demonstrated that mimicking an endogenous gut hormone could produce clinically meaningful weight loss and glycemic control at scale. They also defined what the ceiling looks like, which turned out to be the most important thing they did.
The proof of concept
The class began with exenatide in 2005 — derived from a peptide found in Gila monster saliva that happened to resist the enzyme that degrades native GLP-1. It worked. Not dramatically, but enough to prove that GLP-1R agonism was clinically real and tolerable. Liraglutide followed with better efficacy and once-daily dosing. Dulaglutide pushed to once-weekly.
Semaglutide is where the ceiling became visible. At 2.4mg weekly (Wegovy), it achieved ~15% mean weight loss in the STEP 1 trial — a number that had never been seen from a pharmacological agent in a large Phase 3 trial. It also showed 20% reduction in major cardiovascular events in the SELECT trial, expanding the drug from metabolic disease into cardiology.
That 15% number is both the achievement and the constraint. It represents what single GLP-1R agonism can do at its current dose limit. Getting meaningfully past it requires either tolerating more GI side effects at higher doses, or targeting additional receptors — which is what the next three posts in this series are about.
What defines single GLP-1 agonism
One receptor, multiple effects — GLP-1R is expressed in the pancreas, brain, gut, heart, and kidneys. A single receptor activation drives insulin secretion, glucagon suppression, gastric slowing, and appetite reduction simultaneously. This broad effect profile is why GLP-1 drugs work across multiple endpoints (glycemia, weight, cardiovascular outcomes).
The GI signature — nausea, vomiting, and diarrhea during dose escalation are a direct consequence of GLP-1R's role in slowing gastric motility. This is the class trademark. It's highest during titration and typically self-resolves. Every drug in this family shares it.
The efficacy ceiling — roughly 15% weight loss at the highest commercially viable doses. Not a hard biological ceiling — higher doses push past it — but the GI burden at those doses limits practical use. The ceiling is what motivated dual and triple agonism.
Summary(The single agonist picture)
Single GLP-1 agonists proved the class works and gave us semaglutide as the commercial benchmark. The ~15% weight loss ceiling is real, the cardiovascular benefit is real, and the GI tolerability signature is real. Everything in the next four posts exists because of what this family established — and because of where it stopped.
Semaglutide
At a glance
| Field | Details |
|---|---|
| Brand names | Ozempic (T2D injection), Wegovy (obesity injection), Rybelsus (T2D oral) |
| Targets | GLP-1R |
| Developer | Novo Nordisk |
| Modality | SC injection weekly / oral tablet daily |
| Approval status | Approved — US, EU, global |
| Key efficacy | 14.9% weight loss at 68 weeks (Wegovy 2.4mg, STEP 1) |
| Indications | Type 2 diabetes, obesity, cardiovascular risk reduction |
User Sentiment
The most common thing semaglutide users report isn't the weight loss — it's the quiet. "Food noise" — the constant background hum of thinking about food, planning the next meal, negotiating snacks — just stops. For many people that's the first sign it's working, before the scale moves at all.
Example(What the community says)
r/WegovyWeightLoss has over 150,000 members comparing notes. The recurring themes: nausea in weeks 1–4 that almost always passes, a plateau around month 3 that scares people into quitting right before it breaks, and the surprise of not being hungry at meals they used to overeat at without thinking.
How it works
A long-acting GLP-1 analog with a C18 fatty acid chain that binds albumin in the bloodstream, extending half-life to approximately 7 days and enabling once-weekly dosing. Three formulations, same molecule: Ozempic and Wegovy are subcutaneous injections at different dose ceilings (1mg for T2D, 2.4mg for obesity), and Rybelsus is an oral tablet requiring specific fasting conditions to achieve adequate gut absorption.
GLP-1R activation drives appetite suppression through hypothalamic and brainstem signaling, glucose-dependent insulin secretion, glucagon suppression, and gastric emptying delay — the same mechanism shared by every drug in the single agonist family, at the highest approved systemic exposure level.
Intuition(Why SELECT changed everything)
Wegovy's 14.9% weight loss mattered to obesity medicine. The SELECT cardiovascular outcome trial mattered to cardiology, internal medicine, and payers. A 20% MACE reduction in obese patients without diabetes is a number that justifies prescribing a $1,000/month drug to someone who has no glycemic problem — it reframes GLP-1 therapy from a weight loss drug to a cardiovascular risk drug. That's a different market.
Trial data
STEP 1 (Wegovy 2.4mg, obesity, non-diabetic, 68 weeks): 14.9% mean weight loss. ~32% of participants lost more than 15% of body weight.
SUSTAIN trials (Ozempic, T2D): ~1.5% HbA1c reduction across doses. Consistently outperformed older agents including exenatide and dulaglutide on both glycemic control and weight.
SELECT trial (cardiovascular outcomes, obesity + CVD, no diabetes): 20% reduction in MACE — the trial that expanded semaglutide from a metabolic drug into cardiology and significantly elevated its market positioning.
SURMOUNT-5 (head-to-head vs tirzepatide 2.4mg, 2025): semaglutide produced ~47% less relative weight loss than tirzepatide — the clearest data point on where semaglutide's ceiling sits relative to the dual agonist generation.
What to Expect
Weeks 1–4 — Nausea is common, especially in the first day or two after injection. Eating smaller portions helps. Most people report it fades significantly by week 3.
Month 2 — The food noise starts going quiet. Appetite reduces noticeably. Weight loss of 2–4% is typical by now.
Month 3–4 — A common plateau. Weight loss slows or stalls. This is normal — the body is adjusting. Most people break through it by month 5.
Month 6+ — The 10–15% weight loss range typically lands here for people on 2.4mg maintenance. Energy and mobility improvements often reported alongside the scale changes.
Dosing and administration
Wegovy: 0.25mg weekly → 0.5mg → 1mg → 1.7mg → 2.4mg maintenance over 16–20 weeks. Single-dose pen.
Ozempic: 0.25mg weekly → 0.5mg maintenance (can escalate to 1mg or 2mg for additional glycemic control).
Rybelsus: 3mg daily for 30 days → 7mg → 14mg. Must be taken on an empty stomach with a small sip of water, 30 minutes before any food or other medication.
Development status
| Milestone | Status |
|---|---|
| Ozempic (T2D) | Approved US 2017 |
| Rybelsus (T2D oral) | Approved US 2019 |
| Wegovy (obesity) | Approved US 2021 |
| SELECT (CVD indication) | Approved 2024 |
| Supply normalization | Ongoing — Novo Nordisk manufacturing investment |
Safety profile
Nausea, vomiting, and diarrhea most common — highest during dose escalation, typically self-resolving within 4–8 weeks. Black box warning for thyroid C-cell tumors based on rodent data (clinical significance in humans unclear, no confirmed human cases). Rare pancreatitis. Worsening of diabetic retinopathy observed in some T2D patients with rapid glycemic improvement. Heart rate increase of ~1–2 bpm (class effect).
Who It's For
- BMI ≥ 30, or BMI ≥ 27 with a weight-related condition (high blood pressure, sleep apnea, type 2 diabetes)
- People with type 2 diabetes looking for weight loss alongside glycemic control
- Adults with cardiovascular disease and obesity — SELECT trial data supports this specifically
- Anyone who's tried lifestyle changes without reaching a sustainable result
A provider visit is the next step — they'll confirm eligibility and walk through which formulation fits your situation.
Summary(The semaglutide picture)
The current standard of care across three formulations, two indications, and one proven cardiovascular outcome. SURMOUNT-5 quantified where it sits vs the next generation — ~47% less relative weight loss than tirzepatide at the same 2.4mg ceiling dose. The benchmark everything else is measured against.
Liraglutide
At a glance
| Field | Details |
|---|---|
| Brand names | Victoza (T2D), Saxenda (obesity) |
| Targets | GLP-1R |
| Developer | Novo Nordisk |
| Modality | SC injection, once-daily |
| Approval status | Approved — US (Victoza 2010, Saxenda 2014) |
| Key efficacy | ~8% weight loss at 56 weeks (Saxenda 3mg, SCALE trial) |
| Indications | Type 2 diabetes, obesity, cardiovascular risk reduction |
User Sentiment
Patients who've been on Saxenda longest are often the ones who switched to it before Wegovy was available — and many report it worked well, just with more daily friction. The once-daily injection is the most consistent complaint. Results are real but more gradual than weekly drugs.
Example(What the community says)
Common thread on Saxenda forums: the nausea hits faster and harder with daily dosing than with weekly drugs (higher peak drug levels each day). People who stuck through the first month generally report it settled. Those who quit usually did so in weeks 2–3 when the GI side effects peaked.
How it works
A GLP-1 analog with a C16 fatty acid chain extending half-life to ~13 hours — long enough for once-daily dosing but not weekly. The same albumin-binding mechanism as semaglutide with a shorter chain, resulting in lower peak exposure and a lower efficacy ceiling. Activated GLP-1R drives the same downstream effects as all single agonists: appetite suppression, insulin secretion, glucagon suppression, gastric slowing.
Note(Once-daily vs once-weekly: the adherence gap)
The main clinical disadvantage vs semaglutide isn't efficacy — it's injection frequency. 365 injections per year vs 52. Across a multi-year obesity treatment course that difference is significant. In practice, patients who choose liraglutide over weekly alternatives usually do so for cost or formulary reasons, not preference.
Trial data
SCALE Obesity (Saxenda 3mg, 56 weeks): ~8% mean weight loss. ~63% of participants lost at least 5% of body weight, ~33% lost at least 10%.
LEADER trial (Victoza, T2D, cardiovascular outcomes): ~13% reduction in MACE in patients with high cardiovascular risk — the first GLP-1 drug to demonstrate cardiovascular benefit, establishing the precedent that semaglutide later built on with SELECT.
What to Expect
Weeks 1–2 — Nausea tends to be more pronounced than weekly alternatives because daily injections create higher daily peaks. Eating small, low-fat meals helps.
Month 1–2 — Appetite reduction kicks in. 3–5% weight loss typical.
Month 3–6 — Steady but modest progress. The ~8% average weight loss from SCALE took 56 weeks — this is a slower curve than semaglutide.
Ongoing — Daily injection routine. People who find a consistent time (usually morning) report better adherence than those who inject at variable times.
Dosing and administration
0.6mg/day for one week → 1.2mg → 1.8mg → 2.4mg → 3mg/day maintenance over 5 weeks. Daily injection is the primary practical disadvantage vs semaglutide. Available in a multi-dose pen with dose dial.
Development status
| Milestone | Status |
|---|---|
| Victoza (T2D) | Approved US 2010 |
| Saxenda (obesity) | Approved US 2014 |
| Saxenda pediatric (≥12 years) | Approved 2020 |
| Market position | Declining as semaglutide captures formularies |
Safety profile
GI profile similar to semaglutide — nausea, vomiting, diarrhea most common during titration, self-limiting. Same thyroid C-cell black box warning. Daily injection increases injection site burden vs weekly drugs. Higher discontinuation rates than once-weekly alternatives in head-to-head adherence studies.
Who It's For
- BMI ≥ 30, or ≥ 27 with a weight-related condition
- Patients in markets where Wegovy access or coverage is limited
- People who've already tried semaglutide and want an alternative formulation
- Adolescents 12+ with obesity — Saxenda has pediatric approval that Wegovy doesn't have everywhere
Ask a provider whether liraglutide or a weekly alternative is the right starting point for your situation.
Summary(The liraglutide picture)
The class's first cardiovascular outcome data (LEADER), now largely superseded by weekly drugs on efficacy and adherence. Still relevant where Wegovy isn't covered or in markets where semaglutide access lags. The daily injection burden is the primary practical limitation.
Exenatide
At a glance
| Field | Details |
|---|---|
| Brand names | Byetta (twice-daily), Bydureon BCise (weekly ER) |
| Targets | GLP-1R |
| Developer | AstraZeneca (acquired from Amylin Pharmaceuticals) |
| Modality | SC injection, twice-daily (Byetta) or weekly (Bydureon) |
| Approval status | Approved — US (Byetta 2005, Bydureon 2012) |
| Key efficacy | ~2–3kg weight loss; HbA1c -0.8–1.5% |
| Indications | Type 2 diabetes only |
User Sentiment
Exenatide users are mostly long-term patients who started before weekly options existed, or people on cost-limited plans. Sentiment is mixed — the drug works, but twice-daily injections at meal times is the most cited pain point.
Example(What the community says)
Bydureon (weekly ER) gets better reviews than Byetta (twice-daily) — mostly because injection timing isn't tied to meals. Common complaint with Bydureon: the nodule at the injection site that forms as the microspheres dissolve. It's harmless but noticeable. Most people say they stop noticing it after a few weeks.
How it works
Derived from exendin-4, a peptide found in Gila monster saliva that naturally resists DPP-4 degradation — not a human GLP-1 analog but a structurally distinct peptide that binds and activates the same receptor with similar downstream effects. Not approved for obesity, reflecting its modest weight loss relative to what came after. The first GLP-1RA approved anywhere — approved in 2005 when the class was entirely unproven.
Intuition(Why Gila monster saliva mattered)
Native human GLP-1 has a 2-minute half-life in the bloodstream — degraded almost instantly by the enzyme DPP-4. That made it useless as a drug. Exendin-4, found in Gila monster saliva, activates the same receptor but resists DPP-4 degradation, giving a half-life long enough for twice-daily dosing. The entire GLP-1 drug class exists because a Gila monster peptide happened to bind the human GLP-1 receptor.
Trial data
DURATION trials (T2D): HbA1c reduction of 0.8–1.5%. Weight loss of ~2–3kg — below what the next generation of GLP-1 drugs achieved, but the first clinical evidence that GLP-1R agonism was real and scalable.
EXSCEL trial (cardiovascular outcomes): Non-inferior to placebo on MACE — did not demonstrate the positive cardiovascular signal seen with semaglutide and liraglutide. This is partly attributed to lower systemic exposure and less complete GLP-1R engagement vs later drugs.
What to Expect
Byetta (twice-daily): Nausea right after injection is the most common early experience — usually peaks around 30–60 minutes post-dose and fades. Taking it before the two largest meals (not dinner-only) helps spread the effect.
Bydureon (weekly): Simpler routine, but a small lump forms at the injection site from the microsphere matrix. Typically resolves by next dose cycle.
Month 1–3: Modest appetite reduction. Weight loss slower than semaglutide or tirzepatide — 2–3kg over this period is typical.
Dosing and administration
Byetta: 5mcg twice daily for 4 weeks → 10mcg twice daily. Within 60 minutes before morning and evening meals.
Bydureon BCise: 2mg once weekly, single-dose autoinjector. Extended-release microspheres provide steady drug levels. Eliminates twice-daily burden of Byetta but causes palpable injection site nodules in a subset of patients.
Development status
| Milestone | Status |
|---|---|
| Byetta (T2D) | Approved US 2005 |
| Bydureon (weekly ER) | Approved US 2012 |
| Market position | Declining — limited to cost-sensitive settings |
Safety profile
GI side effects most pronounced with Byetta due to twice-daily peak drug concentration — higher nausea rates than once-weekly formulations. Bydureon causes injection site nodules from microsphere formulation in some patients. Same thyroid black box warning as class. Immunogenicity (antibody formation to the non-human exendin-4 peptide) occurs in some patients, rarely clinically significant.
Who It's For
- Type 2 diabetes patients — exenatide is not approved for obesity in most markets
- Patients where cost is the primary constraint and newer agents aren't covered
- People who've been on it for years and are stable — switching to a newer drug is an option worth discussing with a provider
If you're starting fresh, a provider will almost certainly consider semaglutide or tirzepatide before exenatide. Worth asking why if they recommend it first.
Summary(The exenatide picture)
The proof-of-concept drug for the entire class — approved 2005 when GLP-1 agonism was unproven. Modest efficacy by current standards, but its legacy is in every GLP-1 drug approved after it. Current clinical role is narrow: cost-sensitive settings or patients who can't access newer agents.
Dulaglutide
At a glance
| Field | Details |
|---|---|
| Brand names | Trulicity |
| Targets | GLP-1R |
| Developer | Eli Lilly |
| Modality | SC injection, once-weekly |
| Approval status | Approved — US 2014 |
| Key efficacy | ~3kg weight loss; HbA1c -1.1–1.4% (AWARD trials) |
| Indications | Type 2 diabetes, cardiovascular risk reduction |
User Sentiment
Trulicity has a loyal base — patients who've been on it for years report it as reliable and low-drama. The hidden-needle autoinjector gets consistent praise from people who are anxious about injections. The main sentiment shift has been awareness that tirzepatide produces meaningfully more weight loss.
Example(What the community says)
r/diabetes threads about Trulicity are mostly long-timers sharing stable experiences. New patients asking for comparisons are often pointed toward tirzepatide — which Lilly also makes. The most consistent praise for dulaglutide: the pen. People who were scared of needles report the click-and-done design made self-injection feel manageable for the first time.
How it works
A GLP-1 analog fused to an Fc antibody fragment — the Fc domain extends half-life to approximately 5 days, enabling once-weekly dosing. Structurally distinct from semaglutide's albumin-binding approach but achieving the same pharmacokinetic goal. The Fc fusion also reduces immunogenicity. Lower systemic exposure than semaglutide contributes to its lower efficacy ceiling.
Note(REWIND's broader CV label)
Semaglutide's SELECT trial enrolled patients with established CVD. Dulaglutide's REWIND enrolled patients with or at risk for cardiovascular disease — a broader population that includes primary prevention. That label distinction matters for which patients a cardiologist can justify prescribing it to, even as semaglutide dominates the overall market.
Trial data
AWARD trials (T2D): HbA1c reduction of 1.1–1.4%. Weight loss of ~3kg.
REWIND trial (cardiovascular outcomes): 12% reduction in MACE in T2D patients with or at risk for cardiovascular disease — notably including patients without established CVD, a broader inclusion than the LEADER and SUSTAIN cardiovascular trials, giving dulaglutide a differentiated CV label claim.
What to Expect
Week 1–2 — Generally milder GI side effects than twice-daily exenatide. Nausea is present but typically less intense than daily liraglutide.
Month 1–3 — Steady glycemic improvement in T2D patients. Weight loss is modest (~1–2kg this early).
Month 6+ — The ~3kg average weight loss range from AWARD trials reflects sustained but modest benefit. Stronger glycemic control than weight loss for most users.
Dosing and administration
0.75mg or 1.5mg weekly via single-dose pen with a hidden needle — one of the easier injection devices in the class, designed to reduce injection anxiety. No dose titration required for the 0.75mg starting dose. Can escalate to 3mg or 4.5mg for additional glycemic effect.
Development status
| Milestone | Status |
|---|---|
| Trulicity (T2D) | Approved US 2014 |
| Market position | Declining — Lilly's own tirzepatide outperforms it substantially |
| Pediatric use | Approved for T2D ≥10 years |
Safety profile
GI profile generally milder than twice-daily exenatide and broadly comparable to semaglutide, with lower discontinuation rates in some head-to-head trials. Same class warnings. No novel safety signals in post-marketing surveillance.
Who It's For
- Type 2 diabetes patients, particularly those with cardiovascular risk (REWIND label covers a broad CV population)
- People who are injection-averse — the autoinjector design is genuinely easier than most
- Patients stable on dulaglutide who want to discuss switching to tirzepatide for more weight loss
A provider conversation about whether tirzepatide makes sense as an upgrade is worth having if you're currently on dulaglutide primarily for weight.
Summary(The dulaglutide picture)
A well-designed once-weekly drug superseded clinically by tirzepatide from its own maker. The REWIND cardiovascular label — covering a broader population than SELECT — is the data point that outlasts its market relevance. Still prescribed in cost-sensitive settings and where tirzepatide formulary access lags.
Ecluglutide
At a glance
| Field | Details |
|---|---|
| Brand names | Not yet globally branded |
| Targets | GLP-1R (cAMP-biased agonist) |
| Developer | Sciwind Biosciences / Pfizer (global partnership) |
| Modality | SC injection, once-weekly |
| Approval status | Approved — China 2025. Not yet approved US/EU |
| Key efficacy | ~15.4% weight loss (Phase 3, China) |
| Indications | Obesity |
User Sentiment
Western patient community data is limited — ecluglutide is approved in China but not yet in the US or EU. Early reports from Chinese clinical participants and the Pfizer partnership announcement have generated interest among people tracking the tolerability angle.
Example(What the early data suggests)
Chinese Phase 3 participants reported lower rates of discontinuation due to nausea vs standard comparators — the key claim the biased agonism mechanism is built around. If that holds in global Phase 3, the conversation shifts from "is this better than semaglutide on weight loss?" to "is it better on tolerability at the same weight loss?"
How it works
The first cAMP-biased GLP-1R agonist — mechanistically distinct within the single-agonist class. Standard GLP-1R agonists activate multiple downstream pathways simultaneously: cAMP (which drives insulin secretion and satiety) and β-arrestin (which mediates receptor internalization and contributes to GI side effects). Biased agonism means selectively activating the cAMP pathway while minimizing β-arrestin recruitment.
The hypothesis: if GI side effects are partly β-arrestin mediated, a cAMP-biased agonist could deliver semaglutide-equivalent efficacy with a cleaner tolerability profile. Phase 3 data from China supports competitive efficacy at ~15.4% weight loss with potentially lower discontinuation rates.
Definition(What biased agonism means)
Most receptor agonists activate multiple downstream signaling pathways at once. GLP-1R activation triggers both the cAMP pathway (driving insulin secretion and satiety) and β-arrestin recruitment (mediating receptor internalization — and possibly contributing to GI side effects). A biased agonist preferentially activates one pathway over the other. Ecluglutide's cAMP bias is designed to keep the appetite and metabolic benefits while reducing the β-arrestin-mediated side effects. Whether that works clinically at scale is what global Phase 3 will determine.
Trial data
Phase 3 data from China: ~15.4% mean weight loss — competitive with Wegovy's 14.9% in STEP 1. Tolerability data suggested lower treatment discontinuation rates due to GI adverse events vs unbiased comparators, consistent with the biased agonism hypothesis. Global Phase 3 trials pending through Pfizer partnership.
What to Expect
Based on Phase 3 data from China and the biased agonism mechanism:
Weeks 1–4 — GI side effects expected but potentially milder than standard GLP-1 agonists. The cAMP-biased mechanism is designed to reduce the β-arrestin-mediated nausea component.
Month 2–3 — Weight loss trajectory expected to parallel semaglutide (~15% range). The differentiator is tolerability, not efficacy magnitude.
Global Phase 3 under Pfizer will produce the cleaner Western population data — timeline pending.
Dosing and administration
Once-weekly subcutaneous injection. Specific titration schedule and dose ceiling for the global development program [verify — not fully public].
Development status
| Milestone | Status |
|---|---|
| China approval | 2025 |
| Pfizer global partnership | Active |
| US/EU Phase 3 | Pending initiation — [verify timeline] |
| FDA filing | Timeline not yet public |
Safety profile
Phase 3 data from China shows GI side effect profile consistent with GLP-1 class, with potentially lower discontinuation rates than unbiased agonists. Full global safety database pending Phase 3. No signals specific to biased agonism identified in China Phase 3.
Who It's For
- People who've tried semaglutide and stopped due to intolerable GI side effects
- BMI ≥ 30, or ≥ 27 with a weight-related condition
- Not yet available outside China — check back as global Phase 3 progresses
If you've had to stop a GLP-1 drug due to nausea, ecluglutide is worth watching — it's the only drug in the class specifically designed around that problem.
Summary(The ecluglutide picture)
The only drug in the single-agonist class where the mechanistic innovation is in how GLP-1R is activated, not which receptors are targeted. If the biased agonism tolerability advantage holds in global Phase 3 under Pfizer's partnership, it reopens the single-agonist category at the premium end — same efficacy, fewer side effects.